Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | BAX | Q07812 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12514597 | 0.84 | ALDH1A1 (0.61) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL14319102 | 0.81 | LTA4H (0.61) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL473301 | 0.80 | KDM4E (0.50) | LTA4HTSHRFFAR1FFAR4 | |
| SCHEMBL23098203 | 0.80 | SRD5A2 (0.70) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL19322270 | 0.80 | LTA4H (0.67) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL9906839 | 0.80 | SRD5A2 (0.70) | LTA4HTSHRFFAR1SRD5A2NR1H2 | |
| SCHEMBL28770203 | 0.79 | SOS1 (0.48) | LTA4HSOS1CA1CA2CA9 | |
| SCHEMBL122719 | 0.79 | LTA4H (0.92) | LTA4HTSHRSRD5A2NR1H2BAX | |
| SCHEMBL3893562 | 0.79 | LTA4H (0.92) | LTA4HTSHRSRD5A2NR1H2BAX | |
| SCHEMBL22129853 | 0.79 | LTA4H (0.92) | LTA4HTSHRSRD5A2NR1H2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080107829-A1 | Cellulose compound, cellulose film, optical compensation sheet, polarizing plate, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4742073-A | ANTIGLAUCOMA | BUNDGAARD HANS (DK) | 1988-05-03 | — | — | US | disclosed |
| EP-0106541-A2 | Pilocarpine prodrugs | Bundgaard, Hans (DK) | 1984-04-25 | — | — | EP | disclosed |
| US-4354034-A | Dihalophenoxypropionic acids and their derivatives, and their use as cotton desiccants | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | LTA4H 3093/4885TSHR 162/4885FFAR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.